A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer (FWD1509)

  • End date
    Dec 30, 2025
  • participants needed
  • sponsor
    Forward Pharmaceuticals Co., Ltd.
Updated on 4 October 2022
systemic therapy
measurable disease
neutrophil count
kidney function test
lung carcinoma


The purpose of this study is to characterize the safety and tolerability of FWD1509 MsOH in advanced NSCLC patients and establish the maximum tolerable dose (MTD), recommended phase 2 dose (RP2D) in advanced NSCLC patients.


This study will be a first-in-human study evaluating the safety and tolerability of FWD1509 MsOH in subjects with advanced NSCLC, when FWD1509 MsOH is administered once daily as a single agent. FWD1509 MsOH is an oral TKI (Tyrosine Kinase Inhibitor) that blocks the function of tyrosine kinase. TKIs such as gefitinib, erlotinib or afatinib are recommended as the first-line therapy for EGFR mutated (exon 19 deletions or L858R point mutations in exon 21) NSCLC patients. However, the majority (>50%) of patients will develop acquired resistance after initially responding to gefitinib or erlotinib due to the occurrence of secondary mutations (mostly T709M) in EGFR. Osimertinib was subsequently developed to such secondary mutations, but for EGFRex20ins mutations, on which there is still no effective therapies focusing. FWD1509 MsOH is new generation EGFR-TKI targeting EGFR mutations such as exon 19 deletion, L858R substitution as well as T790M mutations. In particular, FWD1509 MsOH targets the EGFRex20ins mutation in NSCLC. In addition to activity against EGFR mutations, FWD1509 MsOH is also active against a variety of HER2 mutations.

The development of FWD1509 MsOH at this stage is mainly focused on treatment of NSCLC tumors with EGFRex20ins mutations, followed by further exploration against other targets.

Condition Carcinoma, Non-Small-Cell Lung
Treatment FWD1509 MsOH
Clinical Study IdentifierNCT05068024
SponsorForward Pharmaceuticals Co., Ltd.
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Study-Wide Eligibility (Across All Study Parts)
A subject will be eligible for inclusion in this study only if all of the following
criteria apply
Have histologically or cytologically confirmed locally advanced or metastatic NSCLC
(Stage IIIB/IIIC or IV) [JACC edition 8], and inclusion of Stage IIIB only if not a
Must have at least one measurable lesion as defined by response evaluation criteria in
candidate for curative therapy
Prior anti-cancer therapies
solid tumors (RECIST v1.1)
Must have sufficient tumor tissue (either archived sample or recent biopsy) available
for analysis
Phase 1 Dose-escalation part: EGFR and HER2 mutations (including but not limited
toL858R, exon 19 deletion, T790M, ex20ins, 21exon, G719X, S768I, L861Q, etc. for
Male or female adult participants (aged 18 years or older, or as defined per local
EGFR and A775YVMG, C776insVC, P780ins GSP etc. for HER2) should be confirmed by
previously documented evidence or central lab
Adequate organ function at baseline
Patients with both EGFR and HER2 mutations may be included in the dose escalation
Bone marrow function
Phase 1 Dose-expansion part and Phase 2: Have an EGFR in-frame exon 20 insertion
test by any central lab
Absolute neutrophil count (ANC)≥1.5 x 10^9/L
Hepatic function
Platelets ≥100 x 10^9/L
Previously treated with one or more regimens of systemic therapy for locally
Renal function
advanced or metastatic disease
Disease progressed or intolerant to at least one line of systematic therapies
including but not limited to any EGFR-target therapies or immunotherapies, for
metastatic / local relapsed settings
Willingness and ability to comply with scheduled visits and study procedures
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
Minimum life expectancy of 3 months or more
Hemoglobin ≥9 g/dL, criteria must be met without a transfusion within 2
weeks of the blood draw
AST and ALT ≤3 x upper limit of normal (ULN); if liver metastases, then ≤ 5
Bilirubin ≤1.5 x ULN or ≤3 x ULN in the presence of documented Gilbert's
Creatinine clearance ≥50 ml/min (calculated by Cockcroft and Gault equation
(Cockcroft DW, 1976) (Appendix 3)

Exclusion Criteria

Have significant, uncontrolled, or active cardiovascular disease
Have significant, uncontrolled, or active renal disease
Have current spinal cord compression (symptomatic or asymptomatic and detected by
radiographic imaging) or leptomeningeal disease (symptomatic or asymptomatic)
A subject will be not eligible for inclusion in this study if any of the following criteria
Received anticancer therapy including cytotoxic chemotherapy, biological products and
investigational agents, ≤ 21 days prior to first dose of FWD1509 MsOH; or received
prior EGFR TKIs (e.g., gefitinib, erlotinib or osimertinib) ≤7 days prior to the first
dose FWD1509 MsOH
Have been diagnosed with another primary malignancy other than NSCLC except for
patients with adequately treated non-melanoma skin cancer, cervical cancer in situ or
definitively treated non-metastatic prostate cancer, or participants with another
primary malignancy who are definitively relapse-free with at least 3 years elapsed
since the diagnosis of the other primary malignancy
Received radiotherapy ≤14 days prior to the first dose of FWD1509 MsOH or have not
recovered from radiotherapy-related toxicities; palliative radiation administered
outside the chest and brain, stereotactic radiosurgery (SRS), and stereotactic body
radiotherapy are allowed up to 7 days prior to the first dose of FWD1509 MsOH
Received strong CYP3A inhibitors and inducers within 2 weeks prior to the first dose
of FWD1509 MsOH; they should be discontinued at least 2 weeks prior to the first dose
of FWD1509 MsOH and avoided throughout the study duration (see Appendix 6)
Received concomitant medications (e.g., statins) which are substrates of BCRP
p-glycoprotein or OATP1B1/1B3 (dose escalation part of phase 1 study)
Have undergone major surgery within 28 days prior to first dose of FWD1509 MsOH. Minor
surgical procedures, such as catheter placement or minimally invasive biopsy, are
Brain Metastasis: Have known active brain metastases (have either previously untreated
intracranial CNS metastases or previously treated intracranial CNS metastases with
radiologically documented new or progressing CNS lesions), except for the following
Brain metastases are allowed if they have been treated with surgery and/or
radiation and have been stable without requiring corticosteroids to control
symptoms within 7 days before the first dose of FWD1509 MsOH and have no evidence
of new or enlarging brain metastases
Requiring corticosteroids to control symptoms within 7 days prior to the first
dose of FWD1509 MsOH or during study period; patients previously treated for CNS
metastases who are clinically stable, have no new lesions, and who do not need
treatment with a corticosteroid within the 7 days before the first dose of
FWD1509 MsOH and during study period are allowed to be enrolled
QCc-related criteria
A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration
of a QTc interval >480 milliseconds (ms) (CTCAE grade 1) using Fredericia's QT
correction formula
A history of additional risk factors for Torsades de Pointes (TdP) (e.g., heart
failure, hypokalemia, family history of Long QT Syndrome
Have a known history of uncontrolled hypertension (per institution practice)
participants with hypertension should be under treatment on study entry to control
blood pressure
Have any abnormal changes in the cornea or retina that may increase the risk of ocular
toxicity during screening
Have an ongoing or active infection, including but not limited to, the requirement for
intravenous (IV) antibiotics, or a known history of human immunodeficiency virus
(HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Testing is not required in
the absence of history
Currently have or have a history of interstitial lung disease, radiation pneumonitis
that required steroid treatment, or drug-related pneumonitis
Female participants who are lactating and breastfeeding or have a positive urine or
serum pregnancy test during the screening period
Have gastrointestinal illness or disorder that could affect oral absorption of FWD1509
Have any condition or illness that, in the opinion of the investigator, might
compromise participant safety or interfere with the evaluation of the safety of the
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note